Advocacy Groups
This section lists US-based prostate cancer advocacy, education, and support organizations.
This information is offered as a resource to prostate cancer patients and caregivers. The organizations listed are not necessarily endorsed by Ferring Pharmaceuticals Inc.
The AUA Foundation, the world's leading nonprofit urologic health organization, promotes research, education, and advocacy. The foundation’s mission is to promote help, provide hope, and promise a future free of urologic disease.
Malecare is the largest all-volunteer, nonprofit organization in the United States for men diagnosed with cancer.
Men's Health Network (MHN) is a national nonprofit organization whose mission is to reach men and their families where they live, work, play, and pray with health prevention messages and tools, screening programs, educational materials, advocacy opportunities, and patient navigation.
The National Alliance of State Prostate Cancer Coalitions (NASPCC) provides support to existing state prostate cancer organizations, facilitates the development of new state prostate cancer organizations, and serves as a collective and collaborative voice to make prostate cancer a national health care priority.
The Prostate Cancer Foundation, an organization founded to find better treatments and a cure for recurrent prostate cancer, is the largest private source for research funding for prostate cancer. The foundation has funded more than 1,500 programs at nearly 200 research centers in 20 countries around the world.
The Prostate Conditions Education Council is dedicated to saving lives through awareness and the education of men, their partners, and the medical community about the prevalence of prostate cancer, the importance of early detection, available treatment options, and other men's health issues.
The Prostate Health Education Network’s (PHEN) primary mission is to increase prostate health education and awareness among the men in the United States at highest risk for prostate cancer: African Americans. Saving lives through early detection and eliminating the African American prostate cancer disparity are PHEN's education and awareness goals.
Prostate Cancer Awareness Week is initiated by the National Men's Resource Center to inform and educate men on the many issues that confront them today regarding the possible dangers of prostate cancer.
The Prostate Net is engaged in empowering consumers, patients, survivors, and their families and caregivers through education and information to make the appropriate decisions about treating prostate diseases and ensuring the desired quality of life.
Us TOO is dedicated to communicating timely and reliable information enabling informed choices regarding detection and treatment of prostate cancer. The organization offers fellowship, shared counseling, and discussion sessions in both formal and informal settings.
INDICATIONS AND USAGE
FIRMAGON® is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer.
IMPORTANT SAFETY INFORMATION
The most commonly observed adverse reactions during FIRMAGON® therapy included injection site reactions (e.g., pain, erythema, swelling or induration), hot flashes, increased weight, fatigue, and increases in serum levels of transaminases and gamma-glutamyltransferase (GGT). 99% of these observed adverse reactions were Grade 1 or 2 (mild to moderate). Specifically relating to the injection site adverse reactions, most were transient, of mild to moderate intensity, occurred primarily with the starting dose and led to few discontinuations (<1%). Grade 3 (severe) injection site reactions occurred in 2% or less of patients receiving FIRMAGON®.
FIRMAGON® is contraindicated in patients with known hypersensitivity to degarelix or to any of the product components. FIRMAGON® is not indicated in women or pediatric patients. Long-term androgen deprivation therapy prolongs the QT interval. Physicians should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, electrolyte abnormalities, or congestive heart failure and in patients taking Class IA (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications.
Please see the Full Prescribing Information. You can view or download it by clicking on the link in the right-hand column of the page.
The information on this Web site is provided for educational purposes only. While there may be information on this Web site related to certain medical conditions and their treatment, should a medical condition exist, promptly see your own physician or health care provider as the information on this Web site is not intended to take the place of advice from a physician or health care professional. Ferring does not offer personalized medical diagnosis or patient-specific treatment advice. The statements made by doctors on this Web site represent their own individual experiences and opinions and is not intended to be medical advice. Indeed, only your doctor or other health care professional, as a learned intermediary, can determine if a product described in this Web site is appropriate for you.
PLEASE CONSULT WITH YOUR DOCTOR OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL BEFORE USING ANY PRODUCT DISCUSSED WITHIN THIS WEB SITE.
This Web site is intended for US residents only.